GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (NAS:MGNX) » Definitions » Degree of Financial Leverage

Macrogenics (Macrogenics) Degree of Financial Leverage : 0.99 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Macrogenics's Degree of Financial Leverage for the quarter that ended in Dec. 2023 was 0.99. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Macrogenics's Degree of Financial Leverage or its related term are showing as below:

MGNX's Degree of Financial Leverage is ranked worse than
52.14% of 1492 companies
in the Biotechnology industry
Industry Median: 0.97 vs MGNX: 0.99

Macrogenics Degree of Financial Leverage Historical Data

The historical data trend for Macrogenics's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Degree of Financial Leverage Chart

Macrogenics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.04 0.84 0.67 1.03 0.99

Macrogenics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.03 1.02 1.00 1.00 0.99

Competitive Comparison of Macrogenics's Degree of Financial Leverage

For the Biotechnology subindustry, Macrogenics's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Macrogenics's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Macrogenics's Degree of Financial Leverage falls into.



Macrogenics Degree of Financial Leverage Calculation

Macrogenics's Degree of Financial Leverage for the quarter that ended in Dec. 2023 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.15 (Dec. 2023) / -1.95 (Dec. 2022) - 1 )/( -7.628 (Dec. 2023) / -119.758 (Dec. 2022) - 1 )
=-0.9231/-0.9363
=0.99***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Macrogenics  (NAS:MGNX) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Macrogenics Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Macrogenics's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Macrogenics (Macrogenics) Business Description

Industry
Traded in Other Exchanges
Address
9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.
Executives
Ezio Bonvini officer: Sr VP, Research & CSO 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Edward Hurwitz director
Jeffrey Stuart Peters officer: Acting General Counsel 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Margaret Liu director C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804
Meenu Chhabra director C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
James Karrels officer: SVP, CFO and Secretary 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
William K Heiden director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Thomas Spitznagel officer: Sr VP, BPD & Manufacturing 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Federica F. O'brien director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Eric Blasius Risser officer: Sr VP & Chief Business Officer 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Kenneth Galbraith director OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Stephen L. Eck officer: Chief Medical Officer 12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949

Macrogenics (Macrogenics) Headlines

From GuruFocus

MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-04-2023

MacroGenics to Participate in Upcoming Investor Conferences

By sperokesalga sperokesalga 04-24-2023